Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
270.19
+19.04 (7.58%)
At close: May 12, 2025, 4:00 PM
272.00
+1.81 (0.67%)
After-hours: May 12, 2025, 6:48 PM EDT
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $594.19M in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
13.75
Revenue / Employee
$1,052,959
Employees
2,230
Market Cap
35.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ALNY News
- 13 hours ago - Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
- 7 days ago - Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - Business Wire
- 11 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - Business Wire
- 14 days ago - Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 25 days ago - Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - Business Wire
- 6 weeks ago - Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 - Business Wire